Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Payal Sahni Becher is currently the Chief People Experience Officer & Executive VP at Pfizer Inc. She started this position in 2022. Prior to her current role, she obtained a graduate degree from ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Markets expect ...

On May 21, analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer Inc. (NYSE:PFE), reiterating the price target of ...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

These four quality stocks trading at or near their 52-week lows come with stellar dividends that could be massive bargains ...

There are instances where high-yielding stocks can simply be great deals. Three stocks that pay at least 6% and don't look ...

Gujarat Gas Limited, Quess Corp, Power Finance Corporation, and Eris Lifesciences Limited will also report their quarterly ...